Media Release COPENHAGEN, Denmark; July 6, 2026 TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed/refractory (R/R) diffuse large B-cell
Genmab A/S has published its Articles of Association dated June 16, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T:
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12,
Genmab A/S has published its Articles of Association dated June 11, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T:
Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) ineligible for anthracycline-based chemotherapy
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to employees of the Company and the Company's subsidiaries.
Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE ® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R 2) data across subgroups in this trial of relapsed or refractory (R/R) follicular
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical
Genmab A/S has published its Articles of Association dated May 12, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T:
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; May 8, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of May 8, 2026,
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025, to $896 million FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line
Genmab A/S has published its Articles of Association dated March 19, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual General Meeting on March 19, 2026, it was decided to reduce the Company’s share capital with nominally DKK 1,900,000 by cancellation of 1,900,000 of the Company’s holding of shares with a
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of April 13, 2026, Orbis
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that
Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3 RAINFOL-04 trial will further evaluate the
Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. In accordance with Article 19 of Regulation No.
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 31, 2026, Orbis
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of March 27, 2026, Orbis
Genmab A/S has published its Articles of Association dated March 19, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs